Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 4/20 | 0.44 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.40 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 4/20 | 0.40 |
| ▸ | CA12 | O43570 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9811930 | 0.81 | CYP2A6 (0.40) | CYP2A6BCL2L1CA2HDAC3HDAC4 | |
| SCHEMBL29610590 | 0.81 | CYP2A6 (0.40) | CYP2A6BCL2L1CA2HDAC3HDAC4 | |
| SCHEMBL15543762 | 0.75 | — | — | |
| SCHEMBL9396821 | 0.74 | CYP2A6 (0.44) | CYP2A6BCL2L1CA2HDAC3HDAC4 | |
| SCHEMBL2494057 | 0.74 | CYP2A6 (0.44) | CYP2A6BCL2L1CA2HDAC3HDAC4 | |
| SCHEMBL10514091 | 0.73 | CYP2A6 (0.53) | CYP2A6BCL2L1CA2HDAC3HDAC4 | |
| SCHEMBL6539418 | 0.71 | BCL2L1 (0.48) | CYP2A6BCL2L1CA2HDAC3HDAC4 | |
| SCHEMBL1259272 | 0.70 | SLC9A1 (0.53) | CYP2A6BCL2L1CA2HDAC3HDAC4 | |
| SCHEMBL56334 | 0.69 | CYP2A6 (0.48) | CYP2A6BCL2L1CA2HDAC3HDAC4 | |
| SCHEMBL10984367 | 0.67 | CYP2A6 (0.46) | CYP2A6BCL2L1CA2HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LIMITED (GB) | 2012-08-23 | — | — | US | disclosed |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| EP-1786422-A2 | ARYL UREA DERIVATIVES FOR TREATING OBESITY | Prosidion Limited (GB) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006018662-A2 | ARYL UREA DERIVATIVES FOR TREATING OBESITY | PROSIDION LIMITED (GB) | 2006-02-23 | — | — | WO | disclosed |
| US-5106843-A | Treatment of migraine, emesis, anxiety, gastrointestinal disorders, psychological disorders | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-04-21 | — | — | US | disclosed |
| US-4983600-A | Antiemetics, antianxiety agents, gastrointestinal disorders | JOHN WYETH & BROTHER LIMITED (GB) | 1991-01-08 | — | — | US | disclosed |
| EP-0361629-A2 | Heterocyclic compounds | JOHN WYETH & BROTHER LIMITED (GB) | 1990-04-04 | — | — | EP | disclosed |
| EP-0323077-A1 | Heterocyclic compounds | JOHN WYETH & BROTHER LIMITED (GB) | 1989-07-05 | — | — | EP | disclosed |
| US-4069231-A | ANIMAL GROWTH REGULATORS, HERBICIDES | AMERICAN CYANAMID COMPANY (US) | 1978-01-17 | — | — | US | disclosed |
| US-3944567-A | ANIMAL GROWTH REGULATOR, HERBICIDE | AMERICAN CYANAMID COMPANY (US) | 1976-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | CNR1, GPR119, UTS2R | CYP2A6 517/4885BCL2L1 2156/4885CA2 3914/4885 |
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | CNR1, GPR119, UTS2R | CYP2A6 517/4885BCL2L1 2156/4885CA2 3914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.